Advanced

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease

Leuzy, Antoine LU ; Cicognola, Claudia LU ; Chiotis, Konstantinos ; Saint-Aubert, Laure ; Lemoine, Laetitia ; Andreasen, Niels ; Zetterberg, Henrik LU ; Ye, Keqiang ; Blennow, Kaj LU and Höglund, Kina , et al. (2019) In European Journal of Nuclear Medicine and Molecular Imaging 46(5). p.1152-1163
Abstract

Purpose: Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific phosphorylation sites (e.g. threonine 181, P-tau 181p ) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not examine CSF tau levels in relation to cerebral glucose metabolism. We thus aimed to examine CSF tau measures, using both commercial and novel assays, in relation to [ 18 F]THK5317 (tau) and [ 18 F]FDG PET (glucose metabolism). Methods: Fourteen Alzheimer’s disease (AD)... (More)

Purpose: Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific phosphorylation sites (e.g. threonine 181, P-tau 181p ) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not examine CSF tau levels in relation to cerebral glucose metabolism. We thus aimed to examine CSF tau measures, using both commercial and novel assays, in relation to [ 18 F]THK5317 (tau) and [ 18 F]FDG PET (glucose metabolism). Methods: Fourteen Alzheimer’s disease (AD) patients (seven prodromal, seven dementia) underwent [ 18 F]THK5317 and [ 18 F]FDG PET studies, with follow-up performed in ten subjects (six prodromal, four dementia) after 17 months. In addition to commercial assays, novel measures capturing N-terminus+mid-domain (tau N-Mid) and C-terminally truncated (tau-368) fragments were included. Results: While the levels of all forms of CSF tau were found to be inversely associated with baseline [ 18 F]FDG uptake, associations with baseline [ 18 F]THK5317 uptake varied in relation to the degree of isocortical hypometabolism ([ 18 F]FDG SUVR). Changes in the levels of the novel CSF markers tracked longitudinal changes in tracer uptake better than changes in P-tau 181p and T-tau levels, and improved concordance with dichotomized regional [ 18 F]THK5317 measures. Conclusion: Our findings suggest that neurodegeneration may modulate the relationship between CSF and PET tau biomarkers, and that, by comparison to P-tau 181p and T-tau, tau-368 and tau N-Mid may better capture tau pathology and synaptic impairment.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer’s disease, CSF, PET imaging, Tau, [ F]FDG, [ F]THK5317
in
European Journal of Nuclear Medicine and Molecular Imaging
volume
46
issue
5
pages
12 pages
publisher
Springer
external identifiers
  • pmid:30610252
  • scopus:85059651010
ISSN
1619-7070
DOI
10.1007/s00259-018-4242-6
language
English
LU publication?
no
id
24f2f050-8cc9-4791-81d7-fe43e9975da5
date added to LUP
2020-02-25 09:49:58
date last changed
2020-10-20 04:47:36
@article{24f2f050-8cc9-4791-81d7-fe43e9975da5,
  abstract     = {<p>                             Purpose: Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific phosphorylation sites (e.g. threonine 181, P-tau                             <sub>181p</sub>                             ) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not examine CSF tau levels in relation to cerebral glucose metabolism. We thus aimed to examine CSF tau measures, using both commercial and novel assays, in relation to [                             <sup>18</sup>                             F]THK5317 (tau) and [                             <sup>18</sup>                             F]FDG PET (glucose metabolism). Methods: Fourteen Alzheimer’s disease (AD) patients (seven prodromal, seven dementia) underwent [                             <sup>18</sup>                             F]THK5317 and [                             <sup>18</sup>                             F]FDG PET studies, with follow-up performed in ten subjects (six prodromal, four dementia) after 17 months. In addition to commercial assays, novel measures capturing N-terminus+mid-domain (tau N-Mid) and C-terminally truncated (tau-368) fragments were included. Results: While the levels of all forms of CSF tau were found to be inversely associated with baseline [                             <sup>18</sup>                             F]FDG uptake, associations with baseline [                             <sup>18</sup>                             F]THK5317 uptake varied in relation to the degree of isocortical hypometabolism ([                             <sup>18</sup>                             F]FDG SUVR). Changes in the levels of the novel CSF markers tracked longitudinal changes in tracer uptake better than changes in P-tau                             <sub>181p</sub>                              and T-tau levels, and improved concordance with dichotomized regional [                             <sup>18</sup>                             F]THK5317 measures. Conclusion: Our findings suggest that neurodegeneration may modulate the relationship between CSF and PET tau biomarkers, and that, by comparison to P-tau                             <sub>181p</sub>                              and T-tau, tau-368 and tau N-Mid may better capture tau pathology and synaptic impairment.                         </p>},
  author       = {Leuzy, Antoine and Cicognola, Claudia and Chiotis, Konstantinos and Saint-Aubert, Laure and Lemoine, Laetitia and Andreasen, Niels and Zetterberg, Henrik and Ye, Keqiang and Blennow, Kaj and Höglund, Kina and Nordberg, Agneta},
  issn         = {1619-7070},
  language     = {eng},
  month        = {05},
  number       = {5},
  pages        = {1152--1163},
  publisher    = {Springer},
  series       = {European Journal of Nuclear Medicine and Molecular Imaging},
  title        = {Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease},
  url          = {http://dx.doi.org/10.1007/s00259-018-4242-6},
  doi          = {10.1007/s00259-018-4242-6},
  volume       = {46},
  year         = {2019},
}